Success Metrics

Clinical Success Rate
92.3%

Based on 24 completed trials

Completion Rate
92%(24/26)
Active Trials
3(8%)
Results Posted
21%(5 trials)
Terminated
2(5%)

Phase Distribution

Ph phase_4
1
3%
Ph not_applicable
30
79%
Ph phase_2
6
16%

Phase Distribution

0

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution37 total trials
Phase 2Efficacy & side effects
6(16.2%)
Phase 4Post-market surveillance
1(2.7%)
N/ANon-phased studies
30(81.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.3%

24 of 26 finished

Non-Completion Rate

7.7%

2 ended early

Currently Active

3

trials recruiting

Total Trials

38

all time

Status Distribution
Active(5)
Completed(24)
Terminated(2)
Other(7)

Detailed Status

Completed24
unknown7
Terminated2
Recruiting2
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
38
Active
3
Success Rate
92.3%
Most Advanced
Phase 4

Trials by Phase

Phase 26 (16.2%)
Phase 41 (2.7%)
N/A30 (81.1%)

Trials by Status

not_yet_recruiting13%
completed2463%
terminated25%
unknown718%
active_not_recruiting13%
enrolling_by_invitation13%
recruiting25%

Recent Activity

Clinical Trials (38)

Showing 20 of 38 trialsScroll for more
NCT06300060Not Applicable

Synbiotic Supplementation in Cyclists

Completed
NCT07453823Not Applicable

The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals With Excessive Body Weight

Recruiting
NCT05282485Not Applicable

Mitigating Infectious Morbidity and Growth Deficits in HIV Exposed Uninfected infanTs With Human Milk Oligosaccharides

Active Not Recruiting
NCT06901739Not Applicable

Therapeutic Potential of a Synbiotic to Improve Mental Health in Subjects With Obesity.

Recruiting
NCT07048470Not Applicable

Efficacy of Synbiotic Supplementation on IL-10, TGF-B and Disease Activity in Systemic Lupus Erythematosus Patients

Completed
NCT06480812Not Applicable

The Role of Synbiotics in Modulating Host Physiology Via the Gut Microbiome

Completed
NCT06722443Not Applicable

Impact of Nutritional Intervention With Probiotics and Prebiotics on Obesity.

Enrolling By Invitation
NCT06396689Not Applicable

NapBiome: Targeting Gut Microbiota and Sleep Rhythm to Improve Developmental and Behavioral Outcomes in Early Childhood

Not Yet Recruiting
NCT04097106

Synbiotic Dietary Supplement and Gut Microbiota

Completed
NCT04804046Not Applicable

Synbiotics and Post-op Crohn's Disease

Terminated
NCT06160830Not Applicable

The Effects of Synbiotic on Cardiovascular and Bone Metabolism Markers in Transplanted Kidney Patients

Unknown
NCT04639141Not Applicable

Combined Gut-brain Therapy for Children With Autism

Completed
NCT03907501Not Applicable

Effects of Triphala and VSL#3 Probiotic Supplementation on Stool Microbiome Profiles and Inflammation

Terminated
NCT05180201Phase 2

SEPSIS: L. Plantarum Trial

Completed
NCT05405205Not Applicable

Effect of Synbiotic L. Fermentum Strains on Body Fat Mass

Unknown
NCT04754464Not Applicable

Clinical Study on the Effect of a Synbiotic on Body Fat Mass

Completed
NCT05162209Not Applicable

PROBESITY-2: Synbiotics in Pediatric Obesity

Completed
NCT02124759Phase 2

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)

Completed
NCT04960878Not Applicable

The Effect of Synbiotics on the Upper Respiratory Tract Infection

Completed
NCT01680640Not Applicable

Investigation of Synbiotic Treatment in NAFLD

Completed

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
38